6 March 2025 in BMC Nephrology
Corticosteroids are highly efficient for treatment of minimal change disease (MCD), however a substantial number of patients become steroid dependent (SD) or frequent relapsing (FR). Response rate is lower in primary Focal Segmental Glomerulosclerosis (FSGS). Since prolonged exposure to corticosteroids should be avoided, an effective alternative is required. Rituximab is a promising agent. We aimed to evaluate the efficacy of Rituximab in adults with SD/FR nephrotic syndrome (NS). A retrospective cohort study, evaluating patients with SD/FR NS treated with Rituximab in a tertiary hospital. Rituximab was given at induction, with additional doses subjected to the treating nephrologist decision. Primary outcome was number of relapses and time to first relapse. Safety was assessed. Twenty-one adults were included. Among them, 14 (66.7%) were diagnosed with MCD, 5 (23.8%) with FSGS, in 2 cases kidney biopsies were not performed. Median age was 54.6 years. Median follow up was 39.6 months. Number of relapses decreased significantly after Rituximab compared to before treatment (median relapses 0 compared to 3, respectively, W = 3.70, p <.001). Time to first relapse was significantly shorter before Rituximab compared to after (median 11 vs. 536 days, respectively, W = 3.05, p =.002). Hazzard Ratio for relapse was higher in patients who received one Rituximab course compared to those who received an additional maintenance (HR = 4.31, 95% CI: 1.13–16.39, p =.032). Treatment was well-tolerated, serious adverse events included cholecystitis and severe COVID-19. Rituximab emerges as an efficient safe steroid sparing in patients with SD/FR NS, with longer remission achieved when an additional maintenance dose is given after the first course.
6 July 2025 in Expert Review of Respiratory Medicine
To evaluate the efficacy and safety of sotatercept, an activin signaling inhibitor, in pulmonary arterial hypertension (PAH). We searched PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) comparing sotatercept versus placebo in PAH. We calculated pooled risk ratios (RR) and mean differences (MD) with their 95% confidence intervals (CI) using a random-effects model. Heterogeneity was assessed with I2 statistics. The GRADE approach was used to assess the certainty of evidence. Three RCTs comprising 601 patients were included. Compared to placebo, sotatercept significantly improved 6-minute walk distance (MD 40.57 m; 95% CI 26.64 to 54.5; p < 0.01), and WHO functional class (RR 2.04; 95% CI 1.53 to 2.7; p < 0.01). Sotatercept reduced pulmonary vascular resistance (MD -233.18 dyn·sec·cm-5; 95% CI -295.84 to -170.52; p < 0.01) and pulmonary artery pressure (MD -14.94 mmHg; 95% CI -19.62 to -10.27; p < 0.01) at study end. No significant differences were observed in all-cause mortality or NT-proBNP levels. Sotatercept was associated with epistaxis, increased hemoglobin, and telangiectasia adverse events. Sotatercept improves exercise capacity, WHO functional class and pulmonary hemodynamics in PAH, with an acceptable safety profile. Long-term studies are needed to confirm sustained benefits. www.crd.york.ac.uk/prospero identifier is CRD420251032174.
6 August 2025 in BMC Nephrology
In patients with chronic kidney disease, mineralocorticoid receptor antagonists (MRAs) exert a reno-protective effect through its anti-inflammatory and antifibrotic effects. Less is known about the efficacy of MRAs in kidney transplant (KT) recipients. This meta-analysis aims to systematically assess the efficacy of MRAs in KT recipients. PubMed, Embase and Cochrane databases were searched for randomized controlled trials (RCTs) that compared MRAs to placebo in KT recipients and reported the outcomes of (1) glomerular filtration rate (GFR); (2) serum creatinine; (3) systolic (SBP) and diastolic blood pressure (DBP); (4) hyperkalemia; and (5) interstitial fibrosis and tubular atrophy (IFTA) scores. Heterogeneity was examined with I2 statistics. A random-effects model was used for outcomes with high heterogeneity. We included 5 RCTs with 293 patients, of whom 142 (48.5%) underwent treatment with a steroidal MRA. Mean follow-up ranged from 5 days to 36 months. There was no significant difference in GFR (MD 9.04 mL/min/1.73 m2; 95% CI − 2.76–20.85; p = 0.13) and serum creatinine between placebo and MRA groups (MD − 0.21 mg/dL; 95% CI − 0.62–0.20; p = 0.32). SBP (MD 0.69 mmHg; 95% CI − 0.69–2.08; p = 0.33), DBP (MD 0.45 mmHg; 95% CI − 0.69–1.59; p = 0.44) and IFTA scores exhibited no differences between groups (mild IFTA RR 1.21; 95% 0.83–1.74; p = 0.32) (moderate IFTA RR 0.82; 95% CI 0.45–1.50; P = 0.51) (severe IFTA RR 0.64; 95% CI 0.24–1.76; p = 0.39). MRAs were associated with a 4-fold increase in the risk of hyperkalemia compared with placebo (RR 4.06; 95% CI 1.46–11.28; p = 0.007). Steroidal MRAs have no superior efficacy compared with placebo in KT recipients and are associated with a 4-fold increase in the risk of hyperkalemia despite preserved kidney function. Not applicable.